製品名:ethyl 4-ethyl-3-oxohexanoate

IUPAC Name:ethyl 4-ethyl-3-oxohexanoate

CAS番号:91007-16-8
分子式:C10H18O3
純度:95%+
カタログ番号:CM397500
分子量:186.25

包装単位 有効在庫 価格(USD) 数量
CM397500-1000g 3-4 Weeks ȷȦȌƙ

研究開発用専用.

問い合わせフォーム

   refresh    

製品詳細

CAS番号:91007-16-8
分子式:C10H18O3
融点:-
SMILESコード:CCOC(=O)CC(=O)C(CC)CC
密度:
カタログ番号:CM397500
分子量:186.25
沸点:
MDL番号:
保管方法:

Category Infos

Aliphatic Chain Compounds
Aliphatic chain compounds include aliphatic compounds and chain compounds containing other elements or groups. Aliphatic hydrocarbons are hydrocarbons with the basic properties of aliphatic compounds. In aliphatic compounds, carbon atoms are arranged in straight chain, branched chain or cyclic, which are respectively called straight chain aliphatic hydrocarbons, branched chain aliphatic hydrocarbons and alicyclic hydrocarbons. Some cyclic hydrocarbons are different in nature from aromatic hydrocarbons, and are very similar to aliphatic hydrocarbons. Such cyclic hydrocarbons are called alicyclic hydrocarbons. In this way, aliphatic hydrocarbons become a general term for all hydrocarbons except aromatic hydrocarbons. Aliphatic hydrocarbons and their derivatives (including halogenated hydrocarbons) and alicyclic hydrocarbons and their derivatives are collectively referred to as aliphatic compounds.

Column Infos

KB-0742
Kronos Bio announces the first patient dosed in an expansion cohort with KB-0742 at a dose of 80mg given on a four-days-on, three-days-off schedule. This expansion cohort is enrolling platinum-resistant patients with high-grade serous ovarian cancer (HGSOC). Many cancers exhibit transcriptional deregulation, often characterized by gene amplifications of MYC family oncogene. Targeting the transcription elongation cofactor, cyclin-dependent kinase 9 (CDK9) has emerged as a therapeutic strategy to disrupt MYC oncogenic activity.
KB-0742 is an oral highly selective CDK9 inhibitor designed for the treatment of patients with MYC-amplified and other transcriptionally addicted relapsed or refractory solid tumors, including ovarian, lung, and triple-negative breast cancers.